Eligo is building a pioneering platform technology that enables us to engineer phage-derived particles (Eligobiotics®) to package and deliver modular therapeutic DNA payloads to genetically (re)program a wide range of bacterial species in-situ. With such a capability, Eligo is poised to lead the new generation of precision microbiome engineering companies, and address serious unmet medical needs in the field of inflammatory diseases, infectious diseases and oncology.